Hepatitis C Virus: The Next Epidemic, An issue of Gastroenterology Clinics of North America, 1st Edition
Author :
By K. Rajender Reddy, MD, FACP, FACG, FRCP, FAASLD
There are over 180 million people with chronic HCV infection worldwide with between 2.7 and 3.9 million in the United States. Hepatitis C most significantly affects Asia and Africa, with rates up to 15% in countries such as Egypt and up to 30% in cer
...view more
There are over 180 million people with chronic HCV infection worldwide with between 2.7 and 3.9 million in the United States. Hepatitis C most significantly affects Asia and Africa, with rates up to 15% in countries such as Egypt and up to 30% in certain regions such as Punjab, Pakistan. Hepatitis C places a significant burden on the public health infrastructure, as it remains the leading cause of chronic liver disease, accounting for 50-75% of primary liver cancers and is responsible for 30% of all liver transplantations. It is estimated to have cost the United States $5.5 billion in 1997, comparable to the national cost of asthma, $5.8 billion in 1994.This number is only expected to grow as the current HCV population ages, increasing overall rates of compensated cirrhosis/end-stage liver disease. The evolution of directly acting anti-virals has ushered in a new era for chronic hepatitis C. Ongoing drug development strategy has involved targeting several replication steps of the virus and the hope is to see all oral therapies by late 2014 or early 2015. Thus we are at an exciting cross roads with regard to new information and challenges with HCV: rising disease burden with associated high costs, the challenges globally and in multiple patient populations, and the impending availability of effective and well tolerated treatments. Therefore there is a need to commission an exclusive issue of GCNA for HCV.
There are over 180 million people with chronic HCV infection worldwide with between 2.7 and 3.9 million in the United States. Hepatitis C most significantly affects Asia and Africa, with rates up to 15% in countries such as Egypt and up to 30% in certain regions such as Punjab, Pakistan. Hepatitis C places a significant burden on the public health infrastructure, as it remains the leading cause of chronic liver disease, accounting for 50-75% of primary liver cancers and is responsible for 30% of all liver transplantations. It is estimated to have cost the United States $5.5 billion in 1997, comparable to the national cost of asthma, $5.8 billion in 1994.This number is only expected to grow as the current HCV population ages, increasing overall rates of compensated cirrhosis/end-stage liver disease. The evolution of directly acting anti-virals has ushered in a new era for chronic hepatitis C. Ongoing drug development strategy has involved targeting several replication steps of the virus and the hope is to see all oral therapies by late 2014 or early 2015. Thus we are at an exciting cross roads with regard to new information and challenges with HCV: rising disease burden with associated high costs, the challenges globally and in multiple patient populations, and the impending availability of effective and well tolerated treatments. Therefore there is a need to commission an exclusive issue of GCNA for HCV.
Author Information
By K. Rajender Reddy, MD, FACP, FACG, FRCP, FAASLD, Director of Hepatology, Hospital of the University of Pennsylvania, GI Division, Philadelphia, PA
eBooks : Built for busy schedules & tailored for your goals.
Affordable knowledge, built for you
Get the resources you need-often at a lower cost than print. Quality content designed to support your goals, without stretching your budget.
Seamless access wherever you are
Open your eBook on your laptop, tablet, or phone - online or offline. Learning fits into your life, no matter where you go.
Always in sync
Start reading on one device and pick up right where you left off on another. Your progress and notes stay with you, every step of the way.
Tools the make learning stick
Highlight key points, take notes, create flashcards, or listen to your eBook read aloud. Interactive features help you deepen your knowledge, your way.
Your eBook is ready whenever you are!
1. Check your email for your access code.
2. Sign into or create your VitalSource account and redeem your code.
The access code for your new eBook will be sent in your order confirmation email. Your code can also be accessed in your My Account section on the Elsevier webshop.
If you do not receive your code within a few minutes, please check your spam folder.
Step-by-step guidance on how to download Bookshelf and also redeem your code can be found here.
The access code for your new eBook does not expire. However, we always suggest redeeming immediately after purchase to start experiencing the benefits of and insights from your purchase. Important to note - the code provided is a single use code and only valid for the edition you purchase. It does not provide access to past nor future editions of the title.
You will have unlimited access to your eBook on the device to which it was downloaded.
Discover the various learning features that our eBooks offer on the Bookshelf® Reader! For example, you can highlight different text passages, create notes and flashcards, have the text read to you, etc. Particularly practical: You can also use your eBooks offline. More information on the learning functions can be found on the Vitalsource page.
Quality is our top priority. That's why we collaborate with the leading eBook reader provider VitalSource. VitalSource has its own eBook reader Bookshelf®, which you can easily download. This reader is very user-friendly and offers more features than other standard readers. For example, you can highlight different text passages, create notes and flashcards, have the text read to you, etc. Particularly practical: You can also use your eBooks offline. More information can be found on the Vitalsource page.
Elsevier offers its eBooks in ePub format, as we believe this format is best suited to display our content ideally on as many devices as possible.
You can return your eBook within 13 days of purchase. eBooks that have been partially printed or flipped through more than 15% are excluded from returns.
https://www.elsevierhealth.com.au/hepatitis-c-virus-the-next-epidemic-an-issue-of-gastroenterology-clinics-of-north-america-9780323402484.html294599Hepatitis C Virus: The Next Epidemic, An issue of Gastroenterology Clinics of North Americahttps://secure-ecsd.elsevier.com/covers/80/Tango2/large/9780323402484.jpg158.35175.93AUDInStock/Medicine & Surgery/Gastroenterology & Hepatology/Clinics/Medicine/Gastroenterology & Hepatology/Clinics/Clinics/Medicine/Gastroenterology & Hepatology/Product Format/Clinics/Product Format/Clinics/Product Format/Clinics4335139438872550546075054666525504152598945936812593682659368311418269243350884886536505455351451205259833593680959368235936828There are over 180 million people with chronic HCV infection worldwide with between 2.7 and 3.9 million in the United States. Hepatitis C most significantly affects Asia and Africa, with rates up to 15% in countries such as Egypt and up to 30% in certain regions such as Punjab, Pakistan. Hepatitis C places a significant burden on the public health infrastructure, as it remains the leading cause of chronic liver disease, accounting for 50-75% of primary liver cancers and is responsible for 30% of all liver transplantations. It is estimated to have cost the United States $5.5 billion in 1997, comparable to the national cost of asthma, $5.8 billion in 1994.This number is only expected to grow as the current HCV population ages, increasing overall rates of compensated cirrhosis/end-stage liver disease. The evolution of directly acting anti-virals has ushered in a new era for chronic hepatitis C. Ongoing drug development strategy has involved targeting several replication steps of the virus and the hope is to see all oral therapies by late 2014 or early 2015. Thus we are at an exciting cross roads with regard to new information and challenges with HCV: rising disease burden with associated high costs, the challenges globally and in multiple patient populations, and the impending availability of effective and well tolerated treatments. Therefore there is a need to commission an exclusive issue of GCNA for HCV. There are over 180 million people with chronic HCV infection worldwide with between 2.7 and 3.9 million in the United States. Hepatitis C most significantly affects Asia and Africa, with rates up to 15% in countries such as Egypt and up to 30% in certain regions such as Punjab, Pakistan. Hepatitis C places a significant burden on the public health infrastructure, as it remains the leading cause of chronic liver disease, accounting for 50-75% of primary liver cancers and is responsible for 30% of all liver transplantations. It is estimated to have cost the United States $5.5 billion in 1997, comparable to the national cost of asthma, $5.8 billion in 1994.This number is only expected to grow as the current HCV population ages, increasing overall rates of compensated cirrhosis/end-stage liver disease. The evolution of directly acting anti-virals has ushered in a new era for chronic hepatitis C. Ongoing drug development strategy has involved targeting several replication steps of the virus and the hope is to see all oral therapies by late 2014 or early 2015. Thus we are at an exciting cross roads with regard to new information and challenges with HCV: rising disease burden with associated high costs, the challenges globally and in multiple patient populations, and the impending availability of effective and well tolerated treatments. Therefore there is a need to commission an exclusive issue of GCNA for HCV.00add-to-cart97803234024842015ProfessionalBy K. Rajender Reddy, MD, FACP, FACG, FRCP, FAASLD20151Book152w x 229h (6.00" x 9.00")Elsevier07 Dec 2015Please allow 10-14 working days for deliveryBy <STRONG>K. Rajender Reddy</STRONG>, MD, FACP, FACG, FRCP, FAASLD, Director of Hepatology, Hospital of the University of Pennsylvania, GI Division, Philadelphia, PAClinicsClinicsThe Clinics: Internal MedicineG009Gastroenterology & Hepatology, MedicineUnited StatesNoNoNoNoNoPlease SelectPlease SelectNoNoPlease Select